These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 17852035)

  • 1. Intracellular signaling pathways pave roads to recovery for mood disorders.
    Tanis KQ; Duman RS
    Ann Med; 2007; 39(7):531-44. PubMed ID: 17852035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinases as drug targets in the treatment of bipolar disorder.
    Catapano LA; Manji HK
    Drug Discov Today; 2008 Apr; 13(7-8):295-302. PubMed ID: 18405841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers.
    Manji HK; Chen G
    Mol Psychiatry; 2002; 7 Suppl 1():S46-56. PubMed ID: 11986995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of mood stabilizers as plasticity enhancers in the treatment of neuropsychiatric disorders.
    Gray NA; Zhou R; Du J; Moore GJ; Manji HK
    J Clin Psychiatry; 2003; 64 Suppl 5():3-17. PubMed ID: 12720479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mood stabilizers: shared mechanisms of action at postsynaptic signal-transduction and kindling processes.
    Stoll AL; Severus WE
    Harv Rev Psychiatry; 1996; 4(2):77-89. PubMed ID: 9384977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel drugs and therapeutic targets for severe mood disorders.
    Mathew SJ; Manji HK; Charney DS
    Neuropsychopharmacology; 2008 Aug; 33(9):2080-92. PubMed ID: 18172433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics.
    Manji HK; Duman RS
    Psychopharmacol Bull; 2001; 35(2):5-49. PubMed ID: 12397885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of phosphoinositide-protein kinase C signal transduction by omega-3 fatty acids: implications for the pathophysiology and treatment of recurrent neuropsychiatric illness.
    McNamara RK; Ostrander M; Abplanalp W; Richtand NM; Benoit SC; Clegg DJ
    Prostaglandins Leukot Essent Fatty Acids; 2006; 75(4-5):237-57. PubMed ID: 16935483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New understanding of mechanisms of action of bipolar medications.
    Sanacora G
    J Clin Psychiatry; 2008; 69 Suppl 5():22-7. PubMed ID: 19265637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Implications of cAMP signaling in affective disorders].
    Pérez J; Tardito D
    Vertex; 2001; 12(43):21-6. PubMed ID: 11907588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs.
    Gould TD; Manji HK
    Neuropsychopharmacology; 2005 Jul; 30(7):1223-37. PubMed ID: 15827567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postreceptor pathways for signal transduction in depression and bipolar disorder.
    Young LT
    J Psychiatry Neurosci; 2001; 26 Suppl(Suppl):S17-22. PubMed ID: 11590965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting signal transduction pathways in the treatment of mood disorders: recent insights into the relevance of the Wnt pathway.
    Gould TD; Dow ER; O'Donnell KC; Chen G; Manji HK
    CNS Neurol Disord Drug Targets; 2007 Jun; 6(3):193-204. PubMed ID: 17511616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Predictors of prophylactic response to lithium].
    Rohayem J; Baylé JF; Richa S
    Encephale; 2008 Sep; 34(4):394-9. PubMed ID: 18922242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain-derived neurotrophic factor and its receptor tropomyosin-related kinase B in the mechanism of action of antidepressant therapies.
    Kozisek ME; Middlemas D; Bylund DB
    Pharmacol Ther; 2008 Jan; 117(1):30-51. PubMed ID: 17949819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants.
    Hill MN; Hillard CJ; Bambico FR; Patel S; Gorzalka BB; Gobbi G
    Trends Pharmacol Sci; 2009 Sep; 30(9):484-93. PubMed ID: 19732971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipsychotic drug actions on gene modulation and signaling mechanisms.
    Molteni R; Calabrese F; Racagni G; Fumagalli F; Riva MA
    Pharmacol Ther; 2009 Oct; 124(1):74-85. PubMed ID: 19540875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Affective disorders, antidepressant drugs and brain metabolism.
    Moretti A; Gorini A; Villa RF
    Mol Psychiatry; 2003 Sep; 8(9):773-85. PubMed ID: 12931205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GABAergic dysfunction in mood disorders.
    Brambilla P; Perez J; Barale F; Schettini G; Soares JC
    Mol Psychiatry; 2003 Aug; 8(8):721-37, 715. PubMed ID: 12888801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenosine A2A receptor occupancy stimulates collagen expression by hepatic stellate cells via pathways involving protein kinase A, Src, and extracellular signal-regulated kinases 1/2 signaling cascade or p38 mitogen-activated protein kinase signaling pathway.
    Che J; Chan ES; Cronstein BN
    Mol Pharmacol; 2007 Dec; 72(6):1626-36. PubMed ID: 17872970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.